Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 16/20 | 1.00 |
| ▸ | MAPT | P10636 | 12/20 | 1.00 |
| ▸ | MEN1 | O00255 | 11/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 11/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 1.00 |
| ▸ | CASP1 | P29466 | 6/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | PABPC1 | P11940 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.96 |
| ▸ | HPGD | P15428 | 8/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.96 |
| ▸ | RECQL | P46063 | 2/20 | 0.96 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.96 |
| ▸ | BPTF | Q12830 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 8/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | CASP7 | P55210 | 4/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5011418 | 0.78 | ALDH1A1 (0.64) | ALDH1A1MAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL620749 | 0.77 | BPTF (1.00) | ALDH1A1MAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL4051254 | 0.76 | ALDH1A1 (0.64) | ALDH1A1MAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL1719516 | 0.76 | ALDH1A1 (1.00) | ALDH1A1MAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL31381502 | 0.76 | BPTF (0.96) | ALDH1A1MAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL4045538 | 0.74 | ALDH1A1 (0.68) | ALDH1A1MAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL1514467 | 0.73 | BPTF (0.92) | ALDH1A1MAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL4709484 | 0.72 | ALDH1A1 (1.00) | ALDH1A1MAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL4218522 | 0.70 | KRAS (0.56) | ALDH1A1MAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL3765697 | 0.68 | BPTF (0.54) | ALDH1A1MAPTMEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569356-B2 | Cyclin dependent kinase inhibitors | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-10-29 | — | — | US | claimed |
| WO-2007050673-A2 | CYCLIN DEPENDENT KINASE INHIBITORS | UNIVERSITY OF FLORIDA (US) | 2007-05-03 | — | — | WO | claimed |
| WO-2018142365-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018017874-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-01-25 | — | — | WO | disclosed |
| US-8569356-B2 | Cyclin dependent kinase inhibitors | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569356-B2 | Cyclin dependent kinase inhibitors | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120094987-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha | CURACYTE DISCOVERY GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094987-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha | CURACYTE DISCOVERY GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-8058285-B2 | Phosphodiesterase-4 (PDE-4) inhibitors; for treating bronchial asthma, COPD, rheumatoid arthritis (RA), osteoarthritis, cystic fibrosis, Guillain-Barresyndrome, Crohn's disease, ulcerative colitis, psoriasis, atopic dermatitis, allergic eczemas | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| US-8058285-B2 | Phosphodiesterase-4 (PDE-4) inhibitors; for treating bronchial asthma, COPD, rheumatoid arthritis (RA), osteoarthritis, cystic fibrosis, Guillain-Barresyndrome, Crohn's disease, ulcerative colitis, psoriasis, atopic dermatitis, allergic eczemas | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| US-20100035940-A1 | Cyclin Dependent Kinase Inhibitors | UNIVERSITY OF FLORDIA RESEARCH FOUNDATION (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100035940-A1 | Cyclin Dependent Kinase Inhibitors | UNIVERSITY OF FLORDIA RESEARCH FOUNDATION (US) | 2010-02-11 | — | — | US | disclosed |
| EP-1773840-B1 | SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINES AND PYRIDO[3',2':4,5]FURO[3,2-D]-PYRIMIDINES FOR USE AS INHIBITORS OF PDA-4 AND/OR TNF-ALPHA RELEASE | MEDICINES CO LEIPZIG GMBH (DE) | 2010-01-20 | — | — | EP | disclosed |
| US-20080160028-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-ALPHA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
| US-20080160028-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-ALPHA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
| WO-2006010567-A1 | SUBSTITUTED PYRIDO[3', 2': 4, 5]THIENO[3,2-D]PYRIMIDINES AND PYRIDO[3', 2': 4, 5]FURO[3, 2, D]PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF$G(A) | CURACYTE DISCOVERY GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080160028-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-ALPHA | PDE4A, PDE3B, PDE4B | ALDH1A1 367/4885MAPT 3668/4885MEN1 4033/4885 |
| US-20100035940-A1 | Cyclin Dependent Kinase Inhibitors | CCNI, CCNK, CDK1 | ALDH1A1 3139/4885MAPT 3256/4885MEN1 2600/4885 |
| US-20120094987-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha | PDE4A, PDE4B, PDE3B | ALDH1A1 445/4885MAPT 3397/4885MEN1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.